Patents by Inventor David J. Porubek

David J. Porubek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for treatment of bacterial infections with once or twice-weekly administered rifalazil
    Patent number: 7772228
    Abstract: A method for treatment of bacterial infections with rifalazil administered once-weekly, or twice-weekly. A method for treatment of tuberculosis caused by Mycobacterium tuberculosis, infections caused by Mycobacterium avium complex, infections caused by Chlamydia pneumoniae and infections caused by Helicobacter pylori by administering to a patient suffering from the bacterial infection 1-100 mg of rifalazil once or twice a week. In this dose regimen, the treatment is fast, efficacious and eliminates undesirable secondary symptoms observed with daily doses of 1-50 mg of rifalazil.
    Type: Grant
    Filed: September 14, 2002
    Date of Patent: August 10, 2010
    Assignee: Kaneka Corporation
    Inventors: Lynn M. Rose, David J. Porubek, Alan B. Montgomery
  • Method for treatment of bacterial infections with once or twice-weekly administered rifalazil
    Publication number: 20030203903
    Abstract: A method for treatment of bacterial infections with rifalazil administered once-weekly, or twice-weekly. A method for treatment of tuberculosis caused by Mycobacterium tuberculosis, infections caused by Mycobacterium avium complex, infections caused by Chlamydia pneumoniae and infections caused by Helicobacter pylori by administering to a patient suffering from the bacterial infection 1-100 mg of rifalazil once or twice a week. In this dose regimen, the treatment is fast, efficacious and eliminates undesirable secondary symptoms observed with daily doses of 1-50 mg of rifalazil.
    Type: Application
    Filed: September 14, 2002
    Publication date: October 30, 2003
    Inventors: Lynn M. Rose, David J. Porubek, Alan B. Montgomery
  • Method for treatment of bacterial infections with once or twice-weekly administered rifalazil
    Patent number: 6566354
    Abstract: A method for treatment of bacterial infections with rifalazil administered once-weekly or twice-weekly. A method for treatment of tuberculosis caused by Mycobacterium tuberculosis, infections caused by Mycobacterium avium complex, infections caused by Chlamydia pneumoniae and infections caused by Helicobacter pylori by administering to a patient suffering from the bacterial infection 1-100 mg of rifalazil once or twice a week. In this dose regimen, the treatment is fast, efficacious and eliminates undesirable secondary symptoms observed with daily doses of 1-50 mg of rifalazil.
    Type: Grant
    Filed: October 5, 2001
    Date of Patent: May 20, 2003
    Assignee: Kaneka Corporation
    Inventors: Lynn M. Rose, David J. Porubek, Alan B. Montgomery
  • Method for treatment of bacterial infections with once or twice-weekly administered rifalazil
    Patent number: 6316433
    Abstract: A method for treatment of bacterial infections with rifalazil administered once-weekly or twice-weekly. A method for treatment of tuberculosis caused by Mycobacterium tuberculosis, infections caused by Mycobacterium avium complex, infections caused by Chlamydia pneumoniae and infections caused by Helicobacter pylori by administering to a patient suffering from the bacterial infection 1-100 mg of rifalazil once or twice a week. In this dose regimen, the treatment is fast, efficacious and eliminates undesirable secondary symptoms observed with daily doses of 1-50 mg of rifalazil.
    Type: Grant
    Filed: December 15, 1999
    Date of Patent: November 13, 2001
    Assignee: Kaneka Corporation
    Inventors: Lynn M. Rose, David J. Porubek, Alan B. Montgomery
  • Suicide inhibitors of aromatase
    Patent number: 4745109
    Abstract: Thiol-substituted synthetic steriod hormones or androgens having a testosterone ring system backbone are used to inhibit aromatase's catalyzed conversion of C.sub.19 androgens having a A.sup.4,3-ketone group to estrogens in the treatment of estrogen-dependent tumors, such as metastatic breast cancer in postmenopausal females.The compounds have the general formula: ##STR1## wherein R.sub.1 =a thiol, such as --SH or --CH.sub.2 SH, and R.sub.2 =OH or =O. The preferred synthetic hormones are 17.beta.-hydroxy-10.beta.-mercaptoestr-4-en-3-one, 19-mercaptoandrost-4-en-3,17-dione, and 10.beta.-mercaptoandrost-4-en-3,17-dione.
    Type: Grant
    Filed: August 20, 1984
    Date of Patent: May 17, 1988
    Assignee: Washington Research Foundation
    Inventors: Patrick J. Bednarski, David J. Porubek, Sidney D. Nelson